The groundbreaking success of the copyright undeniably reshaped the medication landscape, but investing in companies strongly reliant on generic versions presents a challenging picture. While early profits were substantial, the expiration of patents and the appearance of discounted alternatives have diminished sales. Therefore, a thorough evaluatio